Antisense therapy for malignant disease
- 31 December 1994
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (8) , 1160-1164
- https://doi.org/10.1016/s0959-8049(94)90476-6
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- ANTISENSE THERAPEUTICS IN HAEMATOLOGICAL MALIGNANCIESBritish Journal of Haematology, 1994
- Cationic Lipids Improve Antisense Oligonucleotide Uptake and Prevent Degradation in Cultured Cells and in Human SerumBiochemical and Biophysical Research Communications, 1993
- BCR-ABL antisense purging in chronic myeloid leukaemiaThe Lancet, 1993
- Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?Science, 1993
- Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.Journal of Clinical Investigation, 1993
- Antisense oligomers in chronic myeloid leukaemiaThe Lancet, 1993
- Ablation of Transplanted HTLV-I Tax-Transformed Tumors in Mice by Antisense Inhibition of NF-κBScience, 1992
- Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivoNature, 1992
- Triple Helix-Specific LigandsScience, 1992
- Inhibition of P210BCR/ABL Expression in K562 Cells by Electroporation with an Antisense OligonucleotideLeukemia & Lymphoma, 1990